Eye Drops for Dry AMD: A Non-Invasive Breakthrough

Age-related macular degeneration (AMD), the leading cause of vision loss among individuals over 65, affects millions globally. While dry AMD accounts for 90% of all cases, it can progress into wet AMD, leading to severe vision loss. Traditionally, treatments for dry AMD have been limited to injectable drugs, which, while FDA-approved, have shown modest results and involve invasive procedures with potential complications.

A breakthrough has emerged from the Korea Institute of Science and Technology (KIST), where Dr. Moon-Hyeong Seo and his team developed an eye drop therapy for dry AMD. This new treatment focuses on the inflammatory signaling pathways that play a significant role in the disease’s progression. The team created an extensive peptide library, screening 190,000 candidates to find those capable of targeting Toll-like receptors (TLRs) involved in AMD.

Through extensive research and trials, including tests on mice with induced dry AMD, the new peptide-based eye drops successfully protected retinal cells and significantly reduced degeneration. These drops provide a non-invasive alternative to current injectable treatments, which can be uncomfortable and risky for patients. The eye drop treatment offers greater convenience, better patient adherence, and improved safety—all key factors that could make it a game-changer for dry AMD patients globally.

This advancement not only improves the treatment landscape for age-related macular degeneration but also offers the potential to address other ophthalmic conditions. As researchers at KIST aim to collaborate with international pharmaceutical companies, this innovation is poised to transform how eye diseases are treated, improving accessibility and patient outcomes.

More Information: Lim, Y., et al. (2024). Massively Parallel Screening of Toll/Interleukin‐1 Receptor (TIR)‐Derived Peptides Reveals Multiple Toll‐Like Receptors (TLRs)‐Targeting Immunomodulatory Peptides. Advanced Science. doi.org/10.1002/advs.202406018.